Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. Issue 9 (17th July 2019)

• Record Type: Journal Article
• Authors: Bajaj, Gaurav; Suryawanshi, Satyendra; Roy, Amit; Gupta, Manish
• Is Part Of: British journal of clinical pharmacology. Volume 85:Issue 9(2019)
• Page Start: 2045
• Page End: 2058
• Publication Date: 2019-07-17
• Subjects: cancer -- monoclonal antibodies -- pharmacokinetics -- population analysis; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13996
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: The development of monoclonal antibodies (mAbs) requires an understanding of the interindividual variability (IIV) in pharmacokinetics (PK) at the population level facilitated by population PK (PopPK) modelling. However, there is no clear rationale for selecting which covariates to screen during PopPK model development. Here, we compare the effect of covariates on PK parameters for mAbs in oncology and identify the most commonly used covariates affecting PK parameters. Methods: All 25 mAbs approved for therapeutic use in oncology until December 2017 by the Food and Drug Administration and the European Medicines Agency were selected for study. Literature searches revealed 23 available PopPK models for these mAbs. To understand the magnitude and types of covariate effect on PK parameters, all covariates included in the final PopPK model for each mAb were summarized. Results: The most commonly identified covariates were baseline body weight (BW; 17 mAbs), baseline serum albumin (8 mAbs), and sex (7 mAbs) on clearance; and BW (16 mAbs) and sex (12 mAbs) on central volume of distribution. A reduced PopPK model was developed for nivolumab and ipilimumab using these covariates, and the percentage of explained IIV from the reduced model (20.3% and 16.8%, respectively) was compared with that from the full model (24.5% and 27.9%, respectively). Conclusions: This analysis provides a uniform platform for selecting covariates and suggests that the effect of BW, albumin and sex should be included during the development of PopPK models for mAbs in oncology. The reduced model was able to explain IIV to a similar extent as the full model.